Requirement 1: a chemical neurotoxin, including the first neurotoxin controlled by LHN, is combined with the HC control of the second neurotoxin, wherein the first and the second neurotoxin are different, In LHN domain name, the residual C-terminal is amino acid and propeller 38321； 8320 separates LHN and HC in the first residue of neurotoxin；and wherein the N-terminal amino acid residue of said HC domain corresponds to the second amino acid residue of helix 3₁₀ that separates the LHN and HC domains in said second neurotoxin. Claim 22: A chimeric neurotoxin or pharmaceutical composition according to claim 21, for use in the treatment of a condition associated with unwanted neuronal activity, for example, a condition selected from the group consisting of spasmodic dysphonia, spasmodic torticollis, laryngeal dystonia, oromandibular dysphonia, lingual dystonia, cervical dystonia, focal hand dystonia, blepharospasm, strabismus, hemifacial spasm,Eyelid disorders, cerebral palsy, focal spasm and other speech disorders, spastic colitis, neurobladder, anism, limb spasm, tics, tremor, bruxism, anal fissure, acalasia, Muscular dysregulation and other disorders are characterized by involuntary movement of muscle groups, tears, high water content, excessive saliva, excessive gastrointestinal secretion, secretion disorders, muscle spasm pain, headache, migraine and dermatosis. 19. Claim 23: non therapeutic use of chemical neurotoxins in accordance with any one of claims 1 to 14；Or to treat cosmetic or cosmetic diseases with the pharmaceutical ingredients required by Item 18.Reivindicación 1: Una neurotoxina quimérica que comprende un dominio LHN de una primera neurotoxina unido covalentemente a un dominio HC de una segunda neurotoxina, donde dichas primera y segunda neurotoxinas son diferentes, donde el residuo aminoácido C-terminal de dicho dominio LHN corresponde al primer residuo de aminoácido de la hélice 3₁₀ que separa los dominios LHN y HC en dicha primera neurotoxina； y d
